Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor β receptor type II mice #
Male
Mice, Knockout
0301 basic medicine
Cholangitis
Interleukin-12 Subunit p40
Interleukin-6
Liver Cirrhosis, Biliary
Receptor, Transforming Growth Factor-beta Type II
Protein Serine-Threonine Kinases
Autoimmune Diseases
3. Good health
Mice, Inbred C57BL
Disease Models, Animal
Interferon-gamma
Mice
03 medical and health sciences
Liver
Transforming Growth Factor beta
Animals
Female
Receptors, Transforming Growth Factor beta
Gene Deletion
Signal Transduction
DOI:
10.1002/hep.23132
Publication Date:
2009-06-19T15:00:11Z
AUTHORS (12)
ABSTRACT
Abstract
Our laboratory has reported that mice that express a dominant negative form of transforming growth factor β receptor restricted to T cells (dnTGFβRII) develop an inflammatory biliary ductular disease with elevated serum levels of interleukin (IL)-12p40 and other proinflammatory cytokines and antimitochondrial autoantibodies (AMAs) closely resembling human primary biliary cirrhosis (PBC). We have used this mouse model to address the potential mechanisms of immunomodulation of liver disease by creating two unique genetic strains: IL-12p40 knockout (KO)-dnTGFβRII mice and IFN-γ KO-dnTGFβRII mice. The two colonies of genetically modified mice—and, for purposes of controls, the dnTGFβRII mice—were monitored for liver immunopathology, AMAs, and intrahepatic cytokine production. Disease expression in the IFN-γ KO-dnTGFβRII mice, including liver immunopathology, were similar to those of dnTGFβRII mice, whereas the IL-12p40 KO-dnTGFβRII mice had a dramatic reduction in histological autoimmune cholangitis and significant decreases in levels of intrahepatic proinflammatory cytokines, but similar levels of AMAs compared with dnTGFβRII controls. Conclusion: These data indicate that in this mouse model of PBC, signaling by way of IL-12p40 is an essential requirement for the development of autoimmune cholangitis. The results of these studies will play an important role in identifying pathways and reagents that will selectively inhibit IL-12 signaling for the outlining of future therapeutic strategies for human PBC. (Hepatology 2009.)
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (39)
CITATIONS (99)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....